88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 Inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real-World Data from Both Urban and Rural Clinics
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2020 ◽
Vol 23
(1)
◽
pp. 106-115
◽
2017 ◽
Vol 28
(8)
◽
pp. 2421-2428
◽